The Role of Serum Tumor Markers in Follow-up After Surgical Treatment of Malignant Lung Tumors.
By: Josef Vodicka, Martin Skala, Jakub Sebek, Vladislav Treska, Jakub Fichtl, Kristyna Prochazkova, Bohuslava Vankova, Martin Svaton, Ladislav Pecen, Ondrej Topolcan, Monika Bludovska, Radek Kucera

Department of Surgery, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.
2021-07-21; doi: 10.21873/anticanres.15328
Abstract

Aim

The aim of this study was to evaluate the utility of selected tumor markers for the detection of lung cancer recurrence during follow-up.

Patients

The study group consisted of 109 patients and 109 healthy controls. The following biomarkers were selected: Carcinoembryonic antigen; cytokeratin fragment 19; neuron-specific enolase; tissue polypeptide-specific antigen; cytokeratin fragments 8, 18 and 19; insulin-like growth factor 1; pro-gastrin-releasing peptide; and 25-hydroxyvitamin D. The biomarkers were assessed individually or using a multivariate analysis.

Results

Carcinoembryonic antigen [area under the receiver operating characteristics curve (AUC)=0.6857, p<0.0001] and cytokeratin fragment 19 (AUC=0.6882, p<0.0001) proved best in detecting relapse. The multivariate model indicated insulin-like growth factor 1 (p=0.0006, AUC=0.6225) as the third most useful biomarker. The multivariate model using these three markers achieved the best AUC value of 0.7730 (p=0.0050).

Conclusion

We demonstrated that carcinoembryonic antigen and cytokeratin fragment 19 play a key role in the detection of lung cancer recurrence. A multivariate approach can increase the effectiveness of detection.



Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

PMID:34593462






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements